United Therapeutics Corp. postponed the U.S. launch of its RemoSynch implantable pump for use with the Remodulin therapy for treating pulmonary arterial hypertension.

The system will now be available in 2018 due to regulatory delays. The company developed the RemoSynch system with Medtronic Inc.'s proprietary intravascular infusion catheter, implantable infusion pump and related infusion system components to deliver the drug to treat patients.

United Therapeutics and Medtronic are pursuing parallel regulatory filings for the device and the treatment.